Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetic Characteristics of JYP0061 in Healthy Adult Subjects
NCT06137911Phase 1Completed
- Sponsor
- Guangzhou JOYO Pharma
- Start
- Sep 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JYP0061 in atopic dermatitis (AD) and Neuromyelitis Optica Spectrum Disorder (NMOSD) (6 arms), sponsored by Guangzhou JOYO Pharma. Primary endpoint: Peak Plasma Concentration up to 4 weeks. Started Sep 2021; status: completed.
02
Drugs
JYP0061
03
Conditions
atopic dermatitis (AD)Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT06137911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06137911.